Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Eurofins Scientific    ERF   FR0014000MR3

EUROFINS SCIENTIFIC

(ERF)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Eurofins CDMO : Announces Expansion of Drug Product Capabilities in Canada

11/05/2020 | 08:05am EST

Eurofins CDMO announces the strategic expansion of its existing Drug Product operation capabilities with the early 2020 completion of its new Drug Product development and cGMP manufacturing facility, located in Mississauga, Canada.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201105005535/en/

Eurofins CDMO Alphora Inc. new extension (Photo: Business Wire)

Eurofins CDMO Alphora Inc. new extension (Photo: Business Wire)

The expansion of Eurofins’ Drug Product operations spans 14,500 sq. ft. The assets include fully equipped state-of-the-art pre-formulation and formulation development laboratories, a development suite, multiple GMP manufacturing suites, clinical packaging, and warehousing. With the expansion, Eurofins CDMO can support development and clinical manufacturing of oral solid dosage forms, including Highly Potent API’s. The integration of Drug Product operations compliments Eurofins’ existing API development and manufacturing services by providing an enhanced Quick-to-Clinic drug product strategy designed to meet clients’ needs for phase I and II products.

This complement of services offers science-driven strategies which enhance the Drug Product performance of API’s, from IND enabling through to late stage programs. The new drug product facility allows Eurofins CDMO to offer all drug development services under one roof, achieving enhanced science faster.

About Eurofins CDMO

Eurofins CDMO is a leading global Contract Development and Manufacturing Organization that provides clients with Active Pharmaceutical Ingredients (API’s) / Drug Substance and Drug Product development for small molecules and biologicals. Its service offering encompasses Drug Substance/API Development, Solid State Research and Development, Pre-formulation, Formulation and Development, Analytical Development, GMP Manufacturing and Clinical Packaging and Logistics. Operating with facilities in Europe, North America and India, Eurofins CDMO is accredited through the FDA, EMA, ANSM, ANSES, FAMHP, PMDA, and Health Canada.

For more information: https://www.eurofins.com/cdmo


© Business Wire 2020
All news about EUROFINS SCIENTIFIC
01/18EUROFINS SCIENTIFIC : Bioanalytical Services launches Surrogate Virus Neutralizi..
PU
01/15Eurofins Launches New Test, Increased Capacity to Detect SARS-CoV-2 Variants
MT
01/15EUROFINS : the global leader in analytical testing, expands worldwide face mask ..
BU
01/15EUROFINS SCIENTIFIC : Launches New Tests and Massive Capacity for Detecting and ..
BU
01/11EUROFINS SCIENTIFIC : Anti-COVID-19 System Gets Emergency Response Validation PT..
MT
01/11EUROFINS SCIENTIFIC : GeneScan Technologies Announces AOAC PTM Accreditation for..
BU
2020EUROFINS SCIENTIFIC : Launches Full-Length COVID-19Viral Genome Sequencing Servi..
MT
2020EUROFINS SCIENTIFIC : Genomics Launches Cost-Effective SARS-CoV-2 full-length Vi..
BU
2020EUROFINS CEREP : Launches PCR COVID-19 Self-Test In Germany, Spain
MT
2020EUROFINS SCIENTIFIC : launches COVID-19 PCR tests with at-home self-sampling opt..
PU
More news
Financials
Sales 2020 5 268 M 6 387 M 6 387 M
Net income 2020 405 M 491 M 491 M
Net Debt 2020 2 816 M 3 414 M 3 414 M
P/E ratio 2020 36,7x
Yield 2020 0,66%
Capitalization 14 653 M 17 697 M 17 765 M
EV / Sales 2020 3,32x
EV / Sales 2021 3,06x
Nbr of Employees 48 000
Free-Float 66,7%
Chart EUROFINS SCIENTIFIC
Duration : Period :
Eurofins Scientific Technical Analysis Chart | ERF | FR0014000MR3 | MarketScreener
Technical analysis trends EUROFINS SCIENTIFIC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 73,97 €
Last Close Price 76,80 €
Spread / Highest target 10,8%
Spread / Average Target -3,68%
Spread / Lowest Target -50,3%
EPS Revisions
Managers and Directors
NameTitle
Gilles J. Martin Chairman & Chief Executive Officer
Laurent Lebras Director-Group Finance & Administration
Andreas König Chief Information Officer
Yves-Loïc Martin Non-Executive Director
Valérie Hanote Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
EUROFINS SCIENTIFIC11.90%17 697
SQUARE, INC.4.65%102 701
FISERV, INC.-4.97%72 541
GLOBAL PAYMENTS INC.-11.16%57 287
CINTAS CORPORATION-7.75%34 247
OFFCN EDUCATION TECHNOLOGY CO., LTD.-8.06%31 472